Evidence map›Paper›PMID 28623396›Full record

ArticleAnnals of hematology2017

Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience.

Mao Li, Yongqian Jia, Juan Xu, Xiaomin Cheng, Caigang Xu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mao LiHematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, 37#, Guoxue Lane, Chengdu, Sichuan, 610041, China.
Yongqian JiaHematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, 37#, Guoxue Lane, Chengdu, Sichuan, 610041, China.
Juan XuHematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, 37#, Guoxue Lane, Chengdu, Sichuan, 610041, China.
Xiaomin ChengHematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, 37#, Guoxue Lane, Chengdu, Sichuan, 610041, China.
Caigang XuHematology Research Laboratory, Department of Hematology, West China Hospital, Sichuan University, 37#, Guoxue Lane, Chengdu, Sichuan, 610041, China. xucg@cd120.com.
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating cell-free DNA (ccfDNA) has been shown to be associated with the clinical characteristics and prognosis of cancer patients. Our objective was to assess whether the concentration and integrity index of ccfDNA in plasma may be useful for diagnosing and monitoring the progression of patients with lymphoma. We included plasma samples from 174 lymphoma patients and 80 healthy individuals. The total concentration of ccfDNA was determined using a fluorometry method, and the DNA integrity index (DII), which is the ratio of longer to shorter DNA fragments, for the APP gene was detected using real-time quantitative PCR. The median levels of the ccfDNA concentration and the DII in patients with lymphoma were significantly higher than those in controls (both P < 0.0001). Increases in the ccfDNA concentration and the DII were associated with advanced stage disease, elevated lactate dehydrogenase levels, and a higher prognosis score. In patients with diffuse large B cell lymphoma (DLBCL), high levels of ccfDNA (both concentration and the DII) showed an inferior 2-year progression-free survival (PFS) (P = 0.001; P < 0.0001, respectively). Our study provides quantitative and qualitative evidence in favor of using ccfDNA analysis in lymphoma patients for diagnostic and prognostic assessments.

Indexed as

Biomarkers, TumorDisease ProgressionDNA, NeoplasmFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphomaLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsPrognosisProportional Hazards ModelsReal-Time Polymerase Chain ReactionBiomarkers, TumorDNA, NeoplasmCirculating DNAIntegrityLymphomaPrognosis

Identifiers

PMID28623396
PMCPMC5486778
OpenAlexW2626899352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.